Director, Head of Administration Previously engaged in the pharmaceuticals, diagnostics, biotechnology, and agriscience sectors at Mitsui & Co., Ltd., accumulating a track record in new business development and management of domestic and international affiliated companies in these fields. After serving as the CEO of a drug discovery venture, joined PRISM BioLab, overseeing overall administrative operations....
Yuji Ishiguro is a Full-Time Audit & Supervisory Board Member at PRISM BioLab. After working at House Foods Industrial Co., Ltd. (now House Foods Corporation), he joined Sapporo Beer Co., Ltd. (now Sapporo Holdings Limited). He subsequently held positions as Director and Auditor at subsidiary companies, including Pokka Sapporo Food & Beverage Ltd. and Sapporo...
Mayumi Endo is responsible for computational science. She has over 20 years of deep knowledge and experience in computational chemistry for novel drug discovery, and is one of developers of “Computational Quantum Chemistry” Program, Gaussian. Mayumi joined to PRISM BioLab in 2023, and before joining to PRISM BioLab, she worked for Taisho Pharmaceutical Co., Ltd....
Makoto Fushimi is responsible for medicinal chemistry. He joined in 2025, bringing deep expertise in small molecule drug discovery and positron emission tomography probe research from his work at Takeda Pharmaceutical Co., Ltd. Dr. Fushimi performed collaborative research, including projects at the Tri-Institutional Therapeutics Discovery Institute in New York. With broad experience across therapeutic areas,...
Nobuyuki Hori is responsible for medicinal chemistry. His specialities are organic chemistry and medicinal chemistry. Prior to joining PRISM BioLab, he worked for domestic and global pharmaceuticals in Japan, and engaged in process chemistry and novel drug discovery in infection or metabolic disease area targeting transporters, GPCR, and transcriptional factors. He has led several projects...
Wataru Kawahata is responsible for medicinal chemistry. He has more than 20 years experience in drug discovery research. Prior to joining to PRISM BioLab, he was at Asahi Kasei Pharma for GPCR projects, at Carna Bioscience for kinase projects. He has led the project from the hit finding stage to preclinical stage and identified two...
Takamitsu Maru is responsible for efficacy pharmacology in PRISM BioLab. He has a long experience of compound screening and evaluation for about 20 years at Takeda Pharma and Axcelead DDP. From 2025, he joined PRISM BioLab. Especially, he had contributed to making drug discovery research efficient by developing the preparing method of membrane proteins and...
Yohei Matsuda is responsible for medicinal chemistry and technology platform development. Before joining PRISM BioLab, he worked as a medicinal chemist at Taisho Pharmaceutical Co., Ltd. and engaged in drug discovery research in various disease areas and drug discovery technology development. He was involved in many projects as a chemistry leader and contributed to the...
Jeongho Oak joined PRISM BioLab in 2025 to lead Translational Pharmacology. He brings extensive experience from a postdoctoral fellowship in cardiology at the University of Chicago and from Takeda Pharmaceutical, where he advanced drug discovery projects in cardiovascular and metabolic diseases. At Takeda, he also led nonclinical safety assessment initiatives within the Drug Safety Research...
Yusuke Oka is responsible for medicinal chemistry. Before joining PRISM BioLab, he worked as a medicinal chemist at Taisho Pharmaceutical Co., Ltd., conducting drug discovery research. He has worked as a project leader and manager on multiple drug discovery projects utilizing various modalities, including small molecules, macrolides, and peptides. Through collaborative research, he also has...
Japanese 
English 
